Citigroup
CDIO icon

Citigroup’s Cardio Diagnostics CDIO Stock Holding History

Citigroup’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Sell
1
-25
-96% -$65 ﹤0.01% 5824
2025
Q4 		$70 Buy
+26
New +$95 ﹤0.01% 5686
2025
Q1 		– Sell
-30
Closed -$825 – 5624
2024
Q4 		$825 Buy
+30
New +$416 ﹤0.01% 5608

Other funds holding CDIO

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup's CDIO Position: Q1 2026 in Review

Citigroup reduced its Cardio Diagnostics (CDIO) stake by 96% in Q1 2026, selling an estimated $65 and leaving 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #5824.

Citigroup first reported a position in CDIO in Q4 2024 and has held it in 3 quarters since. The position peaked at $825 in Q4 2024. 16 funds tracked by Wall St. Rank hold CDIO as of Q1 2026.

  • Citigroup held 1 share of Cardio Diagnostics worth $2 as of Q1 2026.
  • Citigroup sold 25 Cardio Diagnostics shares in Q1 2026, an estimated $65.
  • Cardio Diagnostics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5824 holding.
  • Citigroup first reported a position in Cardio Diagnostics in Q4 2024 and has held it in 3 quarters since.
  • Citigroup's Cardio Diagnostics position peaked at $825 in Q4 2024.
  • 16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.